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ABSTRACT
Objective: We investigated whether systemic lupus
erythematosus (SLE) disease duration or serology
associate with abnormal regional glucose metabolism
as measured with [18F]2-fluoro-2-deoxy-D-glucose
positron emission tomography (FDG-PET) and deficits
on neuropsychological testing.
Methods: Subjects with SLE with stable disease
activity, without brain damage or clinical symptoms of
neuropsychiatric (NP) SLE, stratified by disease
duration (short-term (ST)-SLE=disease ≤2 years, long-
term (LT)-SLE=disease ≥10 years), underwent clinical
assessments, neuropsychological testing, resting FDG-
PET scan imaging and measurement of serum titres of
antibody to N-methyl-D-aspartate receptor (DNRAb).
FDG-PET scans were compared with age-matched and
gender-matched healthy controls.
Results: Subjects with LT-SLE demonstrated
hypometabolism in the prefrontal and premotor
cortices that correlated with accrued SLE-related
damage, but not with DNRAb titre or performance on
NP testing. Independent of disease duration, subjects
with SLE demonstrated hypermetabolism in the
hippocampus and orbitofrontal cortex that correlated
with impaired memory performance and mood
alterations (depression, anxiety, fatigue). Serum
DNRAb also correlated independently with impaired
memory performance and increased anxiety. Together,
serum DNRAb titre and regional hypermetabolism were
more powerful predictors of performance than either
alone.
Interpretation: The presence of serum DNRAbs can
account for some aspects of brain dysfunction in
patients with SLE, and the addition of regional
measurements of resting brain metabolism improves
the assessment and precise attribution of central
nervous system manifestations related to SLE.
INTRODUCTION
Cognitive impairment (prevalence range
30–80%) and behavioural disturbances (preva-
lence range 17–75%) including mood disor-
ders and anxiety are common manifestations
of neuropsychiatric systemic lupus erythema-
tosus (NPSLE),1–5 and both demonstrate
signiﬁcant impact on quality of life.6 7
Neuropsychological testing has revealed abnor-
malities in a wide range of cognitive domains
in patients with SLE;1 2 8–12 however, attribu-
tion of neuropsychiatric abnormalities to a
pathological mechanism associated with SLE is
hampered by the confounding inﬂuences of
medications, infections, comorbid disease, hor-
monal and metabolic disturbances. There is
currently no speciﬁc biomarker or battery of
tests that distinguish SLE-mediated cognitive
and behavioural dysfunction. Such a bio-
marker would be essential for the develop-
ment of therapeutic strategies for these
problems.
DNRAbs are a subset of anti-dsDNA anti-
bodies that cross-react with N-methyl
D-aspartate receptors (NMDARs) on neurons;
they have been shown to enhance synaptic sig-
nalling resulting in neuronal activation, dys-
function or death depending on antibody
concentration.13 In the murine model,
DNRABs mediate impairments in memory and
behaviour.14 15 While associations between
serum DNRAbs and cognitive and behavioural
KEY MESSAGES
▸ Autoantibodies directed against the NMDA recep-
tor, DNRAb, are known to mediate neuronal tox-
icity. FDG-PET imaging may provide a biomarker
for DNRAb-mediated cognitive and behavioral
dysfunction.
▸ FDG-PET imaging demonstrates increased
regional metabolism in the hippocampus of SLE
subjects compared to healthy controls, irrespect-
ive of disease duration. Both DNRAb serum titres
and increased hippocampal metabolism were
independent predictors of poor memory perform-
ance; the two predictors together improved the
accuracy of the predictions made based on either
individual measure alone.
▸ Decreased metabolism in the prefrontal cortex
and premotor cortex correlates with long term
disease and overall damage and not with DNRAb.
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changes in human SLE have remained inconclusive,16 ele-
vated DNRAb titres in cerebrospinal ﬂuid (CSF) correlate
with severe non-focal manifestations of NPSLE, such as sei-
zures, acute confusional state, mood and anxiety disorders,
psychosis and cognitive dysfunction.16–20 DNRAbs have
also been identiﬁed in the CSF and brain tissue of patients
with SLE who died with symptoms of cognitive
impairment.15 21
The blood–brain barrier (BBB) does not normally
allow antibody access to the brain; however, it is known
that BBB permeability is altered in response to hyperten-
sive episodes, nicotine, infection, stress and alcohol.22–25
We hypothesised that patients with SLE experience
repeated breaches of BBB integrity, thereby allowing
intermittent access of circulating autoantibodies to brain
tissue. This hypothesis predicts that patients may exhibit
increased autoantibody-mediated central nervous system
(CNS) damage over time independent of measures of
disease activity or damage in other organs, as we and
others have previously demonstrated.26 Furthermore, it
predicts an increase in CNS injury corresponding to
longer disease duration.
We investigated the relationship among resting brain
glucose metabolism, cognitive and behavioural perform-
ance, and serum DNRAb titres in stable patients with SLE
with short-term (ST-SLE; disease ≤2 years) and long-term
duration disease (LT-SLE; disease ≥10 years), and no acute
or chronic CNS symptoms. Previous [18F]2-ﬂuoro-2-deoxy-
D-glucose positron emission tomography (FDG-PET)
studies in patients with long-standing SLE report reduced
metabolism in structurally intact brain regions,27–30 which
may precede further clinical deterioration.30 Both hypo-
perfusion and hyperperfusion on FDG-PET scans in
patients with active NPSLE symptoms and normal MRI
have been reported,31 and diffuse hypermetabolism in
white matter tracts has been reported in newly diagnosed
patients with SLE and interpreted as CNS inﬂammation
related to systemic disease activity.32 To date, there are no
reported relationships among regional alterations in
glucose metabolism, serology and cognitive and behav-
ioural assessments in patients with SLE. This cross-
sectional study was designed to test the hypothesis that
SLE disease duration, and thus some measure of repeated
exposure to a neurotoxic autoantibody, DNRAb, will asso-
ciate with abnormal regional glucose metabolism and deﬁ-
cits on neuropsychological testing.
PATIENTS AND METHODS
Subject selection
All 17 subjects with SLE were 18 years of age or older and
fulﬁlled the American College of Rheumatology (ACR)
revised criteria for SLE. The SLE subject characteristics are
found in table 1. Subjects were recruited randomly from
the Rheumatology Clinics at the Feinstein Institute for
Medical Research (FIMR) and were selected by disease
duration; nine had ST-SLE (disease duration ≤2 years) and
eight had LT-SLE (disease duration ≥10 years). Patients
with SLE with active NPSLE (as deﬁned by the ACR33), a
history of NPSLE or other CNS event, were excluded to
avoid the confounding effects of active or prior CNS
insults on the imaging and neuropsychological endpoints.
Additionally, all subjects with SLE were required to have
stable disease activity and medication doses for 4 weeks
prior to screening and pertinent exclusion criteria
included current use of antidepressant, antipsychotic or
anxiolytic drugs or history of illicit drug use. Seventeen
healthy controls (HCs), selected from a cohort of resting
FDG-PET imaging studies at the Center for Neurosciences
in the FIMR, were matched for gender and age.
Clinical and behavioural assessments
Measures of disease activity, the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI)34 and
accrued damage, the Systemic Lupus International
Collaborating Clinics Damage Index (SLICCDI),35 were
assessed within two weeks of PET imaging. Cognitive func-
tion was assessed on the day of imaging using the auto-
mated neuropsychological assessment metric (ANAM).36
This neuropsychological battery comprised a set of com-
puterised measures of sustained attention, visual search,
computational skills, concentration, spatial and cognitive
processing, and working memory. Throughput scores,
representing a combination of reaction time and accuracy,
were the primary measure of cognitive processing used in
the analyses. ANAM subtests were also grouped according
to their representative cognitive domains and their mean
total throughput scores (TTS) were correlated with metab-
olism and serology.37 38 Subjects were additionally rated
for depression, anxiety and fatigue with the Beck
Depression Inventory, State-Trait Anxiety Inventory and
the ANAM assessment of mood domains (vigour, restless-
ness, depression, anger, fatigue, anxiety and happiness).
ELISA
Serum DNRAb assays were performed by ELISA with the
DWEYS consensus sequence as the substrate as previ-
ously described.39
Positron emission tomography
Following an overnight fast, subjects with SLE and HC
underwent FDG-PET imaging as described in detail else-
where.40 Scanning was conducted in 3-D mode using the
GE Advance tomograph (General Electric Medical
Systems, Milwaukee, Wisconsin, USA) at the FIMR.
Autoradiographic PET images were acquired for 20 min
beginning 35 min after the injection of 3.5 mCi FDG in
an eyes-open rest state in a dimly lit room with minimal
auditory stimulation. Following scan preprocessing, indi-
vidual images were non-linearly warped into Talairach
space using a standard PET template, and smoothed
with an isotropic Gaussian kernel (10 mm) in all direc-
tions to improve the signal-to-noise ratio. Investigators
blinded to subject identity, clinical status, duration of
symptoms and DNRAb level conducted data acquisition
and analysis.
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Imaging analysis
A voxel-wise search of whole brain volume using the two-
sample t test option in SPM5 (Institute of Neurology,
London, UK) was performed to assess group differences
in regional metabolic activity among the combined SLE
groups, ST-SLE and LT-SLE, and HCs. SPM (T) maps
were created for each group and threshold at T=3.4,
p=0.001 (peak voxel, uncorrected). Group differences
were considered signiﬁcant for p<0.05, corrected at the
cluster level. Metabolic activity in signiﬁcant brain
regions was assessed using spherical (radius=5 mm)
volumes of interest (VOIs), centred at the peak voxel of
each cluster. In each VOI, globally normalised values
were compared between groups using one-way analysis
of variance (ANOVA) with post hoc Bonferroni tests;
results were considered signiﬁcant at p<0.05, two sided.
Statistical analysis
Baseline characteristics of subjects with SLE, ANAM
subtest throughput scores and TTS scores were analysed
using t tests or non-parametric Mann–Whitney U tests.
Relationships among resting regional metabolism,
ANAM subtest scores and mood scores, serum DNRAb
titres and clinical parameters were examined using
Pearson’s correlations (r) or Spearman’s correlations
(rs) for abnormally distributed data. Multiple regression
analysis was used to test whether DNRAb and metabolic
activity could improve the prediction of performance on
neuropsychological tests for subjects with SLE. Analyses
were performed using SPSS V.12 (SPSS, Chicago,
Illinois, USA). All tests were two-sided, and signiﬁcance
was set at p<0.05.
RESULTS
SLE clinical characteristics and ANAM scores
There were no clinical differences between the ST-SLE
and LT-SLE groups other than an expected increase in
the mean SLICCDI in the LT-SLE group (table 1).
ST-SLE and LT-SLE groups performed comparably in
mean throughput scores or TTS on all of the ANAM subt-
ests and the mood domains. C3, C4, anti-dsDNA and
anti-Ro antibody titres, SLEDAI scores, SLICCDI, use of
disease-modifying drugs and prednisone dose also did
Table 1 SLE subject characteristics
Short term n=9
(disease ≤2 years)
Long term n=8
(disease ≥10 years) p Value
Age 34.22±9.72 41.23±8.04 0.134
Gender: % female 100 100 na
Ethnicity ns
African American 22% 63%
Hispanic 44% 37%
Caucasian 22% 0%
Asian 12% 0%
Education (years) 14.67±2.4 12.29±6.05 0.296
SLEDAI 2.22±2.05 3.25±3.2 0.437
Damage index 0.33±0.5 1.25±0.71 0.007*
STAI 36.44±11.77 35±7.96 0.774
BDI 10.78±11.16 6.88±3.72 0.346
Prednisone 2.64±3.45 2.06±2.86 0.715
Anti-dsDNA titre* 1.03±0.66 1.12±0.92 0.819
DNRAb titre 0.30±0.15 0.29±0.09 0.774
Frequency DNRAb+ 66.7% 54.5% 0.858
Frequency anti-Ro+ 33.3% 50% 0.486
C3 107.56±25 117.13±19.9 0.4
C4 20.89±6.11 24.5±13.24 0.47
Hydroxychloroquine 55.6% 87.5% 0.183
Current disease-modifying antirheumatic drug use 55.6% 62.5% 1.0
Methotrexate 22.2% 0 0.265
Cellcept 11.1% 50% 0.131
Azathioprine 22.2% 12.5% 1.0
Cyclophosphamide 0 0 na
Hypertension† 11% 38% 0.294
Diabetes mellitus† 0 0 na
Smoking (ever) 22.2% 25% 0.665
All data are reported as frequency (%) or as mean±SD. All data for medications (prednisone, hydroxychloroquine and immunosuppressive
medications) refer to current use at the time of evaluation.
*Mean anti-dsDNA titre by ELISA in Diamond lab using same sera as the DNRAb titre.
†Current hypertension or diabetes mellitus requiring medication.
BDI, Beck Depression Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; STAI, State Trait Anxiety Inventory.
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not signiﬁcantly correlate with ANAM subtest throughput
scores or with depression and anxiety ratings.
Resting metabolic abnormalities in subjects with SLE
Brain regions with signiﬁcant changes in metabolic activ-
ity in the combined SLE groups relative to HCs are pre-
sented in table 2A. A voxel-by-voxel search of the whole
brain volume revealed signiﬁcantly increased
metabolism in the SLE groups (ﬁgure 1, top) involving
the hippocampus, orbitofrontal cortex (Brodmann area
(BA) 11), posterior putamen and globus pallidus.
Analysis of individual metabolic data from these regions
(ﬁgure 1, bottom) disclosed abnormal increases in sub-
jects with both ST-SLE (p<0.03) and LT-SLE (p<0.003,
post hoc Bonferroni tests) relative to the subjects with
HC (p<0.001, one-way ANOVAs). Metabolic activity in
these regions did not differ between the two SLE sub-
groups (p>0.27). Additionally, there were no differences
in global metabolic rate between the SLE and HC
groups (p>0.10) or between the two SLE subgroups
(p>0.09).
In contrast, there were signiﬁcant reductions in meta-
bolic activity (ﬁgure 2, top; table 2B) in the prefrontal
(BA 9, p<0.05; BA 10, p<0.001, post hoc Bonferroni
tests) and premotor (BA 6, p<0.05) regions in the
LT-SLE relative to subjects with ST-SLE. The subjects
with LT-SLE, but not the subjects with ST-SLE, also dis-
played decreased metabolic activity in the prefrontal
cortex compared with the HCs (BA 9, p<0.05; BA 10
p<0.005, post hoc Bonferroni test) (ﬁgure 2, bottom).
The premotor cortex (BA 6) changes among HC and
SLE groups did not reach signiﬁcance (p>0.21).
Correlations between metabolic activity and cognitive/mood
testing in subjects with SLE
Metabolism in the left hippocampus (ﬁgure 3A) corre-
lated with impaired performance on the running
memory continuous performance test (RMCPT, r=−0.61,
Table 2 Brain regions with significant differences in
metabolic activity (A) between subjects with SLE and
healthy controls; (B) between subjects with LT-SLE and
ST-SLE
Brain region
Coordinates*†
Zmax x y z
(A) Metabolic increases in SLE compared with HC
Hippocampus
Right 4.01 24 −22 −10
Left 3.32 −28 −28 0
Orbitofrontal cortex, BA 11
Right 3.54 28 38 −14
Left 4.35 −22 40 −14
Putamen/globus pallidus, right 3.79 26 −26 0
(B) Metabolic decreases in LT-SLE compared with ST-SLE
Prefrontal cortex, BA 9, left 3.66 −20 42 20
Prefrontal cortex, BA 10, left 3.92 −10 58 10
Premotor cortex, BA 6, left 3.37 −24 8 48
*Montreal Neurological Institute standard space.55
†p<0.001, uncorrected; p<0.05, corrected for cluster extent.
BA, Brodmann area; HC, healthy controls; LT, long term; SLE,
systemic lupus erythematosus; ST, short term.
Figure 1 Voxel-based comparisons of FDG-PET images for SLE and healthy control subjects. SLE subjects (n=17) were age-
matched and gender-matched with HCs (n=17). The SLE subjects demonstrated significantly increased metabolic activity (top) in
the hippocampus (A), orbitofrontal cortex (BA 11, B) and putamen/globidus pallidus (GP, C) compared to HCs. In each region
(bottom; p<0.001, one-way ANOVAs), metabolic activity was higher (p<0.05) in SLE subjects (open and filled triangles) than HC
subjects (open circles), but did not differ (p>0.27) between the ST-SLE (open triangles) and LT-SLE (filled triangles) groups.
Statistical parametric maps (SPM) were superimposed on a single-subject MRI brain template and thresholded at T=3.4, p<0.001
(uncorrected). Metabolic increases are color coded from red to yellow. The left side (L) is labeled on the display.
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p<0.01). Metabolic activity in the left orbitofrontal cortex
also correlated with impaired performance on the code
substitution (CST, r=−0.65, p<0.005) (ﬁgure 3D), CST
delayed (r=−0.50, p<0.05) and memory search (r=−0.52,
p<0.04) tests. Mean TTS on ANAM subtests that included
assessments of sustained attention (CST, CST delayed,
math processing and memory search) also demonstrated
a correlation with left orbitofrontal hypermetabolism and
impaired performance (r=−0.5, p<0.05). Similarly, meta-
bolic activity in the right orbitofrontal region correlated
inversely with performance in math processing (r=−0.51,
p<0.04) and memory search (r=−0.59, p=0.01). No corre-
lations were identiﬁed between cognitive or behavioural
performance and basal ganglia metabolic activity.
Signiﬁcant correlations were identiﬁed between increas-
ing right hippocampal metabolism and ANAM scores
for depression (ﬁgure. 3B, r=0.58, p<0.02), anxiety
(ﬁgure 3C, r=0.52, p<0.04) and fatigue (r=0.53, p<0.03).
Increased left orbitofrontal metabolism also correlated
with increased anxiety (r=0.61, p=0.01).
Correlations of cognitive/mood testing and metabolic activity
with serum DNRAb and other autoantibodies
DNRAb serum titres correlated inversely with mean TTS
for ANAM subtests that included measurements of
sustained attention (see above) and working memory
(CST delayed, match-to-sample, memory search, RMCPT)
(r=−0.66, p<0.005). Signiﬁcant correlations were identi-
ﬁed between increasing serum DNRAb titres and worsen-
ing throughput scores on the RMCPT (r=−0.72, p<0.002),
CST (r=−0.56, p<0.03) and match-to-sample (r=−0.56,
p<0.03). Increasing serum DNRAb titres also correlated
with greater impairment on tests of depression (r=0.73,
p=0.001) and anxiety (r=0.64, p<0.008). Serum levels of
anti-dsDNA and anti-Ro antibodies did not signiﬁcantly
correlate with performance on any of the ANAM subtests
or mood assessments.
DNRAb serum titres correlated with increased meta-
bolic activity in the left hippocampus (r=0.53, p<0.04)
and orbitofrontal cortex (r=0.50, p<0.05). Metabolic
activity in these regions did not correlate with the clinical
assessments of complement components, anti-dsDNA or
anti-Ro AAb titres, SLEDAI scores, SLICCDI, prednisone
dose, age or with the use of disease-modifying drugs.
Both DNRAb titres (R2=0.51, p<0.002) and increased
left hippocampal metabolic activity (R2=0.37, p<0.01)
were independent predictors of memory performance
(RMCPT) (ﬁgure 4A). Importantly, the two measures in
concert improved (R2=0.67, p<0.0008, multiple regres-
sion analysis) the accuracy of the predictions made
based on either of the individual measures. Similarly,
DNRAb titres and increased left orbitofrontal
Figure 2 Voxel-based comparisons of FDG-PET images for SLE subjects with different disease duration and HC. Significantly
decreased metabolic activity (top) was present in the prefrontal cortex (BA 9 and 10, A and B) and the premotor cortex (BA 6, C)
of the LT-SLE subjects. The LT-SLE subjects (filled triangles) demonstrated significant hypometabolism compared to the ST-SLE
subjects (open triangles) in each of these areas (bottom; p<0.05, one-way ANOVAs). However, compared to HCs (open circles),
the LT-SLE subjects demonstrated significant hypometabolism only in the prefrontal cortex (p<0.05, A, B). Metabolism in the
prefrontal and premotor regions did not differ significantly between the ST-SLE subjects and HCs. Statistical parametric maps
(SPM) were superimposed on a single-subject MRI brain template and thresholded at T=3.4, p<0.001 (uncorrected). Metabolic
decreases are color coded from blue to green. The left side (L) is labeled on the display.
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metabolism together provided a better prediction
(R2=0.44, p<0.03, multiple regression analysis) of mood
disturbance (anxiety) than each measure individually
(DNRAb titre, R2=0.31, p<0.03; orbitofrontal metabol-
ism, R2=0.37, p=0.01) (ﬁgure 4B).
Metabolic abnormalities related to disease duration
Disease duration exhibited an inverse relationship with
metabolic activity in the prefrontal (BA 9, rs=−0.58,
p<0.02; BA 10, rs=−0.53, p<0.03) and premotor (BA 6,
rs=−0.56, p<0.02) regions (ﬁgure 2). The SLICCDI,
which measures damage accrued from SLE, comorbid
conditions and/or medication, was higher (p=0.007) in
the subjects with LT-SLE (table 1), and it correlated with
declining metabolic activity in the prefrontal regions
(BA 9, r=−0.52, p<0.04; BA 10, r=−0.46, p=0.06).
DISCUSSION
The data suggest that distinct potential mechanisms for
neurotoxicity underlie alteration of CNS function in
SLE. SLE disease duration associates with depression of
resting glucose metabolism in the prefrontal cortex, and
this regional hypometabolism also associates with
accrued damage (related to disease activity, comorbid
disease, infections and medications) but not with serum
DNRAb titres or assessments of cognitive performance
and mood. Increased glucose metabolism in the hippo-
campus and orbitofrontal cortex in subjects with SLE is
independent of disease duration and is linked to serum
DNRAb titres, memory impairment and mood altera-
tions. Importantly, serum titres of other autoantibodies,
anti-dsDNA and anti-Ro antibodies, do not correlate
with regional hypermetabolism or function. These clin-
ical data are consistent with candidate mechanisms for
DNRAb neurotoxicity established in the animal model
where memory impairment and behavioural alteration
are associated with DNRAb effects on NMDAR
physiology.
Interpretation of these ﬁndings depends on timing and
a more complete understanding of regional glucose
hypermetabolism that may represent a compensatory
neuronal response to damage, a localised inﬂammatory
response or both. We and others have reported increased
cortical activation patterns in subjects with SLE compared
with HCs, implying increased recruitment of neural net-
works as a compensatory response.41–43 Accordingly,
recent micro-PET studies combined with brain histopath-
ology in a murine model of DNRAb-mediated neuron
toxicity revealed hippocampal hypermetabolism asso-
ciated with a decreased number of neurons following
BBB breach with lipopolysaccharide (LPS) in DNRAb
positive mice with circulating DNRAb. These mice also
exhibited impaired spatial memory. This was in contrast
to the DNRAB negative control mice that exhibited hip-
pocampal hypermetabolism following BBB breach with
LPS but with a normal hippocampal neuron number and
no functional impairment.44 Increased hippocampal
metabolism in the DNRAb negative control mice likely
represents an inﬂammatory response to LPS as there
Figure 3 Correlation between resting metabolism in SLE subjects and cognitive or behavioral performance. Increased
metabolism in the left hippocampus correlated with poor performance on the running memory continuous performance test
(RMCPT), a measure of sustained attention (A, p<0.01). Increased metabolism in the right hippocampus correlated with
increased depression and anxiety scores (B and C, p<0.05); and increased metabolism in the left orbitofrontal cortex correlated
with poor performance on the code substitution test, a measure of visual search, sustained attention and memory (D, p<0.005).
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were no behavioural or histopathological consequences.
Conversely, the hippocampal hypermetabolism that
inversely correlated with neuron number in the DNRAb
positive mice exposed to LPS suggests a compensatory
neuronal response. Our ﬁndings suggest that
DNRAb-mediated insults in human disease may also
lead to a compensatory neuronal response, local
inﬂammation or both with functional consequences. The
powerful predictive value of hippocampal hypermetabo-
lism and serum DNRAb for cognitive and behavioural
performance in this cross-sectional study has implications
for efﬁcacy measures in a therapeutic trial, but the ﬁnd-
ings will ﬁrst need to be validated in a longitudinal study.
Many proinﬂammatory molecules have been identi-
ﬁed in the CSF of patients with NPSLE in addition to
autoantibodies.45–47 The presence of elevated Q
albumin, a clinical mark of BBB breach, or reversible
neuron dysfunction on magnetic resonance spectroscopy
studies in patients with SLE with active disease and no
overt symptoms of NPSLE, supports the hypothesis that
patients with SLE can experience a CNS inﬂammatory
response in the absence of apparent CNS symptoms,48 49
analogous to the LPS-induced localised brain inﬂamma-
tory response in mice.44
We also detected signiﬁcant glucose hypermetabolism
in the orbitofrontal cortex that was signiﬁcantly corre-
lated with impaired performance on ANAM subtests
requiring sustained attention and increased anxiety
ratings in these individuals. The orbitofrontal lobe parti-
cipates in executive processes such as regulation of cog-
nition and emotion.50 It is also part of a neural circuit
that communicates with the amygdala, a centre for emo-
tional learning and processing of fearful stimuli;51 this
may contribute to the observed correlation with sus-
tained attention. The signiﬁcant correlations between
hippocampal hypermetabolism and increased depres-
sion, anxiety and fatigue and orbitofrontal metabolism
and anxiety corroborate prior reports of serum DNRAb
titres linked to mood disturbances.16 Perhaps most
importantly from a mechanistic perspective, the meta-
bolic increases in the three regions are unrelated to
each other. This is unlike the patterned network dys-
function that has been identiﬁed in primary neuronal
degenerations like Parkinson’s disease.52 Thus, it is pos-
sible that some of the neuropsychiatric manifestations
observed in SLE result from autoantibody-mediated
brain events that target different regions independent of
each other.
Interestingly, regional hypermetabolism did not correl-
ate with disease duration. This is consistent with previous
reports of brain involvement early in disease.12 32 53 It is
possible that functional outcome measures may correlate
with disease duration among a subgroup of subjects with
chronically elevated titres of serum DNRAb; however, a
larger longitudinal study would be needed to test this.
Disease duration did correlate with metabolic decline in
the prefrontal and premotor cortical regions. Moreover,
prefrontal cortex hypometabolism correlated with the
SLICCDI, suggesting that these changes reﬂect the sus-
tained, accumulated effects of SLE activity, comorbid
disease and/or medications, on regional brain function
over extended periods of time. The comparable perfor-
mances of the LT-SLE and ST-SLE groups on the ANAM
tests and mood assessments, combined with the lack of
association between DNRAb and the hypometabolic
Figure 4 Predictive model of memory performance and
mood alteration with serum DNRAb and metabolism in SLE.
A. Multiple regression analysis demonstrates that the
combined influence of elevated serum DNRAb titers (yellow)
and increasing metabolism in the hippocampus (red) better
predicts memory impairment in cognitive performance (blue)
in the SLE patients (R2=0.67, p<0.0008) than either measure
alone (hippocampal metabolism: R2=0.37, p<0.01; DNRAb:
R2=0.51, p<0.002). B. Similarly, the combined effects of
serum DNRAb (yellow) and increasing orbitofronal
metabolism (red) are a more powerful predictor of increased
anxiety (blue) (R²=0.44, p<0.03) than either measure
independently (DNRAb: R²=0.31, p<0.03; orbitofrontal
metabolism: R²=0.37, p=0.01).
Mackay M, Tang CC, Volpe BT, et al. Lupus Science & Medicine 2015;2:e000074. doi:10.1136/lupus-2014-000074 7
Biomarker studies
areas, suggest that time-dependent mechanisms interact
with receptor physiology and pathology to produce
brain dysfunction distinct from direct DNRAb toxicity.
In summary, the use of FDG-PET imaging, serology
and neuropsychological assessments has identiﬁed strik-
ing predictors of cognitive and behavioural performance
in this cross-sectional study. While serum DNRAbs and
regional brain hypermetabolism associate independently
with functional consequences, in combination they are a
more powerful predictor of performance than either
alone. Our ﬁndings are informed further by a murine
model of DNRAb neurotoxicity that demonstrates
separate mechanisms for glucose hypermetabolism;
a compensatory response of neurons surviving DNRAb-
mediated neurotoxicity and a localised inﬂammatory
response to BBB disruption.44 The regional hypermeta-
bolism demonstrated by subjects with SLE in this study
may reﬂect localised inﬂammatory responses that can be
triggered by a variety of insults to the BBB. However,
consistent with the murine model, memory impairment
and mood disturbance associate signiﬁcantly with serum
DNRAb titres. It is likely that other mechanisms are
responsible for the regional hypometabolism that associ-
ates with disease duration and the SLICCDI. The results
of this study suggest that composite variables including
regional measurements of resting brain metabolism may
improve the prediction of CNS manifestations attribut-
able to SLE and longitudinal studies will be necessary to
evaluate this. Elucidating the speciﬁc mechanisms that
contribute to different CNS manifestations of SLE is an
important direction for research in SLE and will be best
accomplished through coordinated studies of patients
and murine models.
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